الفهرس | Only 14 pages are availabe for public view |
Abstract I N 1’ R 0 ll U C T I 0 N iJJ~O:Xlil nas occunied a prominent place in the management of l1eC1 rt dilated cardioruyupathy d!Jd opt irna.l use 01 Ciigr_):xin Cl>nsidE•r<JbJ t:: to:x1c rat j o of thi~ drug. A sound understanding the dCliUJlS ctnd ]Jllarrnacukinetics of digoxin l s essential of to TnlllJ 1(!17(’ l1f· t-.·\·i;C-·r-presen1 rj s1-- of toxicity and to provide maximum henr)fi i_ to the patient Cong<c~llve heart failure is associated ll’ith hypoperfusion to \”i·tJ’L(’liS o.r-;2ctnc:. lJJcluaillg the sites of drug excretion, e.g. liver Tl1P pla~ma cone11trations of drugs are usuall~· higl1er 111 :;,_!-. lP:J-t’-> \•.-itr, conges\i\·t_, hec:i.rt failure than health_\” sub_jects .Silftllclrl\·, l!J patier1ts ~ith im1Jaired lei dney function, p1 asmr1 lP\C’JS 01 orugs are The changes ln phdrmacukinetics assume usually importance higher. onl~v 1n case of drugs with a narrow therapeutic absorption of digoxin ratio (e.g. digoxin). 1s esse11tlal]y a pass)ve The non intestinal saturable dilfu~iOll process. The bioavailab1lity var1es between 40- 100 %. Serum suspected corfq) l j Rnce digoxin toxicity, monitoring should be done, especially for doubts about efficacy or 1n cases of poor A |